FDA Panel To Vote On Hologic’s Permanent Birth Control Device Next Month
This article was originally published in The Gray Sheet
Hologic's PMA for the Adiana permanent female birth control product will be considered by an FDA advisory panel Dec. 13, the agency said Nov. 8
You may also be interested in...
The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues
In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.
The new ALS product is a fixed-dose combo of two ingredients – sodium phenylbutyrate and taurursodiol – that some patients currently are compounding. Amylyx says it will explore ‘all options’ in addressing that, noting its strong IP for Relyvrio, but also committing to access.